Exclusive: Biogen shortens name, expands ambitions in Alzheimer's, ALS

NEW YORK (Reuters) – Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.




Source: Business

Leave a Reply

Your email address will not be published. Required fields are marked *

17 − thirteen =